Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LOS ÁNGELES, April 15, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) ha anunciado hoy Agentic Financial Operations, un nuevo modelo operativo destinado a resolver el principal reto que...
-
BlackLine presenta Agentic Financial Operations per risolvere il gap di governance e fiducia dell’IA
LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) ha presentato oggi Agentic Financial Operations, un nuovo modello operativo progettato per affrontare la sfida chiave...
-
LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) heeft vandaag Agentic Financial Operations aangekondigd, een nieuw operationeel model dat gericht is op het aanpakken van...
-
LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) hat heute Agentic Financial Operations vorgestellt, ein neues operatives Modell, das die zentralen Herausforderungen in...
-
LOS ANGELES, 15 avr. 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq : BL) annonce aujourd’hui le lancement d’Agentic Financial Operations, un nouveau modèle opérationnel visant à remédier aux...
-
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich, Germany, April 15, 2026 - Vivoryon Therapeutics N.V. (Euronext...
-
ASML reports €8.8 billion total net sales and €2.8 billion net income in Q1 2026ASML now expects 2026 total net sales to be between €36 billion and €40 billion, with a gross margin between 51% and 53%...
-
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
-
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...
-
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its...